Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone Duration for Nephrotic Syndrome in Young Children
NCT03141970Phase 3Completed
- Sponsor
- AIIMS New Delhi
- Start
- Jul 2015
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of prednisolone in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by AIIMS New Delhi. Primary endpoint: Relapse of nephrotic syndrome during 12 months after randomization. Started Jul 2015; status: completed.
02
Drugs
prednisolone
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT03141970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141970.